Dr. de Wit on Rationale for Phase III CARD Trial in Metastatic CRPC

Video

Ronald de Wit, MD, PhD, discusses the rationale for the randomized phase III CARD trial which showed a significant overall survival benefit with third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer.

Ronald de Wit, MD, PhD, group leader, Experimental Systematic Therapy of Urogenital Cancers program, Erasmus MC Cancer Institute, Rotterdam, Netherlands, discusses the rationale for the randomized phase III CARD trial which showed a significant overall survival (OS) benefit with third-line cabazitaxel (Jevtana) in patients with metastatic castration-resistant prostate cancer (mCRPC).

Docetaxel and the androgen signaling inhibitors, abiraterone acetate (Zytiga) and enzalutamide (Xtandi) are frequently used in the metastatic castration-resistant setting. However, once patients progress on one of the androgen signaling inhibitors, they are not likely to respond to the other agent, de Wit explains. Cabazitaxel, though available, is often used as the last intervention.

As such, patients in the CARD trial were randomized to receive either cabazitaxel or abiraterone or enzalutamide, depending on which androgen signaling inhibitor they had received previously.

After a median follow-up of 9.2 months, investigators reported a median OS of 13.6 months with cabazitaxel versus 11.0 months with either abiraterone or enzalutamide (HR 0.64; 95% CI 0.46—0.89; P =.008).

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD